Tag: Advanced Accelerator Applications

Pamela Kunz, MD_Yale Appointment 2020

News and Notes from the Carcinoid Cancer Foundation, October 2021

October 11, 2021
Dr. Pamela Kunz Named Woman Oncologist of the Year

Congratulations to NET expert Pamela Kunz, MD, who was named Woman Oncologist of the Year! Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal…

READ MORE
Lisa Yen, LACNETS

Lisa Yen Selected as 2020 Monica Warner Award Recipient

May 27, 2021

Congratulations to Lisa Yen, NP, NBC-HWC, of LACNETS upon being selected as the 2020 Monica Warner Award recipient! The award, established by Novartis Oncology in 2009, is presented annually to “honor a patient, supporter, or caregiver who most embodies…

READ MORE
Monica Warner Award_3

2020 Monica Warner Award: Call for Nominations

December 10, 2020

Advanced Accelerator Applications (AAA), a Novartis company, has announced that nominations are open for the 11th Annual Monica Warner Award!  AAA is continuing the Novartis tradition of sponsoring the award, which commemorates the life and work of…

READ MORE
Lu-177

FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

January 26, 2018

BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors

READ MORE
Bicycle

NET Community Bicycle Raffle Recipients

November 10, 2017

In conjunction with Worldwide NET Cancer Awareness Day, November 10, the Carcinoid Cancer Foundation and Advanced Accelerator Applications are very excited to announce recipients of the recent Bicycle Giveaway Raffle.

Stefano Buono, CEO of Advanced…

READ MORE
2015-highlights

Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations (updated January 26, 2019)

April 6, 2017

The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.

PLEASE SCROLL DOWN FOR A STATE-BY STATE LIST READ MORE
fighting-net-cancer-with-grace-gratitude_2

Fighting NET Cancer with Grace and Gratitude

November 9, 2016

The Carcinoid Cancer Foundation is very excited to share what we have planned around this year’s Worldwide NET Cancer Awareness Day, November 10, and hope you will help us spread the word about NET cancer to support and inspire one another, and those yet…

READ MORE
Big Apple NETs_0

October Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

September 1, 2016

Join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Luncheon with the Experts in New York City on Sunday, October 16, 2016.  This special program was initiated and is sponsored by the Big Apple NETs support group,…

READ MORE
Lu-177

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an Expanded

READ MORE
Diane Reidy Lagunes, MD, Memorial Sloan Kettering_2

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

March 23, 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

READ MORE